HeartBeam Inc. (NASDAQ: BEAT) announced that its management team will participate in several investor and industry conferences throughout March 2026. The company's presence at these events highlights its ongoing efforts to engage with the financial and medical communities regarding its technology for transforming cardiac care.
CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17. During the conference, the company will host a webcast presentation on March 16 and conduct meetings with institutional and retail investors. This participation provides an opportunity for HeartBeam to communicate its business strategy and technological advancements directly to the investment community.
The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24. At this event, CEO Robert Eno will join a panel discussion focused on technologies that advance healthy aging. This forum allows HeartBeam to position its cardiac monitoring solutions within the broader context of preventative healthcare and aging population needs.
Additionally, Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology's annual scientific conference on March 28-30. At this premier cardiology event, the company plans to showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
HeartBeam's technology represents a significant advancement in cardiac monitoring. The company is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever patients are located, potentially enabling physicians to identify cardiac health trends and acute conditions outside traditional medical facilities.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. The Cleared Indications for Use for the HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment can be found at https://www.heartbeam.com/indications. HeartBeam holds over 20 issued patents related to its technology enablement.
For business and technology leaders monitoring the healthcare technology sector, HeartBeam's conference participation signals the company's continued progress in commercializing its innovative cardiac monitoring solutions. The demonstration of its extended-wear patch prototype at ACC.26 represents a potential expansion of its product portfolio beyond its current FDA-cleared system. As remote patient monitoring and telehealth continue to evolve, technologies like HeartBeam's that enable comprehensive cardiac assessment outside clinical settings could reshape how cardiovascular conditions are detected and managed, potentially reducing healthcare costs and improving patient outcomes through earlier intervention.
